Screener
Generate Biomedicines, Inc. GENB Q3 2026 earnings
Reported November 12, 2026 · Before market open
Revenue$4.2MMiss by $3.5M
EPS-$0.68Miss by $0.12
Revenue estimate$7.8M
EPS estimate-$0.56
“Our third quarter results reflect both strong execution across all of our clinical programs and our continued efforts to push the frontiers of programmable biology and therapeutic intelligence. We are making strong progress with GB-0895 in severe asthma, and the data we shared at ERS in COPD further demonstrated the sustained pharmacological activity to support robust modulation of key biomarkers and twice-a-year dosing. At the same time, our scientists are extending the impact of our platform, from new CAR T engineering to our collaboration with Anthropic on agentic science. We start with what a therapy needs to do, then engineer and test the biology to get there.”
Next report
Feb 11, 2027 (in 3 months)Revenue estimate$6.3M
EPS estimate-$0.67
Financials
Q3 2026Valuation & ratios
Versus estimates
Revenue
Q3 2026$4.2MMiss by $3.5M
Q2 2026$6.3MBeat by $1.0MDiluted EPS
Q3 2026-$0.68Miss by $0.12
Q2 2026-$0.52Miss by $0.01FAQ
- When did Generate Biomedicines, Inc. report Q3 2026 earnings?
- Generate Biomedicines, Inc. (GENB) reported Q3 2026 earnings on November 12, 2026 before market open.
- What were Generate Biomedicines, Inc.'s Q3 2026 revenue and EPS?
- Generate Biomedicines, Inc. reported revenue of $4.2M and eps of $-0.68 for Q3 2026.
- Did Generate Biomedicines, Inc. beat estimates in Q3 2026?
- Revenue missed the consensus estimate of $7.8M by $3.5M. EPS missed the consensus estimate of $-0.56 by $0.12.
- Where can I find Generate Biomedicines, Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-456921) and the 10-Q periodic report (0001193125-26-456890) directly on SEC EDGAR. The filing index links above go to sec.gov.
